Real-world effectiveness of biologic therapies in severe asthma patients ineligible for phase 3 randomised controlled trials of biologics: an analysis from the UK Severe Asthma Registry
Ineligibility by typical RCT inclusion/exclusion themes was generally not associated with inferior biologic composite response. Asthma biologics are effective in a broad range of patients, many of whom would not have met clinical trial eligibility criteria.
Authors
- J Karaj
- John Busby (ORCID: https://orcid.org/0000-0003-4831-7464)
- Hassan Burhan (ORCID: https://orcid.org/0000-0002-5521-0748)
- Salman Siddiqui
- Hitasha Rupani (ORCID: https://orcid.org/0000-0002-0150-138X)
- Paul Pfeffer
- David J. Jackson (ORCID: https://orcid.org/0000-0002-2299-868X)
- Rekha Chaudhuri (ORCID: https://orcid.org/0000-0001-8007-949X)
- Pujan H. Patel
- Mitesh Patel
- Kathryn Prior
- Liam Heaney
- Thomas D. Brown (ORCID: https://orcid.org/0000-0002-2123-1014)
Institutions
- Queen's University Belfast (GB)
- Lancashire Teaching Hospitals NHS Foundation Trust (GB)
- University of Liverpool (GB)
- Queen Mary University of London (GB)
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Barts Health NHS Trust (GB)
- Aintree University Hospitals NHS Foundation Trust (GB)
- Gartnavel General Hospital (GB)
- Derriford Hospital (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- Portsmouth Hospitals NHS Trust (GB)
- Royal Brompton Hospital (GB)
- Lung Institute (US)
- Imperial College London (GB)
- University of Glasgow (GB)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1183/23120541.00565-2025
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00